{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-097007","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.623850+00:00","generated_at":"2026-05-31T09:16:25.362333+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Lyra Therapeutics Q2 net loss $48.1M; workforce cut 75%; ENLIGHTEN 1 subgroup positive","bullets":["Q2 net loss $48.1M vs $15.6M YoY, including $22.8M right-of-use asset impairment and $6.5M restructuring charge.","Cash $67.5M at June 30; expects runway into Q1 2026.","Further analysis of ENLIGHTEN 1 shows LYR-210 improved 3CS score by 2.25 points (p=0.0058) vs sham in CRS with nasal polyps.","Reduced workforce by ~75% (87 employees), halted manufacturing, paused LYR-220, and seeking subleases.","ENLIGHTEN 1 extension results expected Q4 2024; ENLIGHTEN 2 topline results expected 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-097007","json":"https://secwatch.observer/filing/0000950170-24-097007.json","markdown":"https://secwatch.observer/filing/0000950170-24-097007.md","text":"https://secwatch.observer/filing/0000950170-24-097007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/0000950170-24-097007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/lyra-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:16:25.362333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}